newsfilter
← Latest News
GlobeNewswire·

RenovoRx Strengthens Scientific Advisory Board (SAB) with Pancreatic Cancer Expert Timothy Donahue, MD

  • RenovoRx, Inc. (NASDAQ: RNXT) appointed Timothy Donahue, MD, a pancreatic disease expert & Director of UCLA's Agi Hirshberg Center for Pancreatic Diseases, to its scientific advisory board.
  • Dr. Donahue leads a high-volume clinical program integrating extended induction therapy with surgery for locally advanced pancreatic cancer & serves as Principal Investigator of an NIH-funded research laboratory.
  • Ramtin Agah, MD, RenovoRx's Chief Medical Officer, stated Dr. Donahue's expertise will inform the development of localized therapies for difficult-to-treat tumors.
  • Dr. Donahue praised RenovoRx's Trans-Arterial Micro-Perfusion (TAMP™) platform for increasing local drug concentration & expressed excitement to support its potential to improve survival & quality of life.
  • RenovoRx is evaluating the drug-device combination product candidate IAG (intra-arterial gemcitabine via RenovoCath) in the ongoing Phase III TIGeR-PaC trial.
  • The IAG combination product received Orphan Drug Designation for pancreatic cancer & bile duct cancer, granting seven years of market exclusivity upon FDA approval.
  • RenovoRx commercializes the FDA-cleared RenovoCath device & announced its first commercial purchase orders in December 2024, with several high-volume National Cancer Institute-designated centers initiating repeat orders.
  • The company plans to explore further revenue-generating activities for its TAMP technology through independent efforts or partnerships with medical device commercial entities.
  • The press release includes a cautionary note regarding forward-looking statements & lists various risks that could cause actual results to differ materially from projections.